GGrantIndex
Sort

23,748 grants matching melanoma

Oncogenic Met Signaling in Urologic Malignancies

$522,479
Donald Bottaro · Division Of Basic Sciences - Nci · ZIA · FY2019 · CA

Tissue Resident memory T cell responses to cancer

$522,276
Mary J Turk · Dartmouth College · R01 · FY2022 · CA

6-thio-2'-deoxyguanosine in GBM: Pre-clinical Evaluation of Mechanism of action, Efficacy and Biomarker identification

$522,189
David M. Ashley · Duke University · U19 · FY2022 · CA

Targeting Systems Vulnerabilities in the Gαq/GNAQ Oncogenic Signaling Circuitry: New Precision Therapies for Uveal Melanoma

$522,110
J. Silvio Gutkind · University Of California, San Diego · R01 · FY2025 · CA

An integrated approach to melanoma metastasis and therapy resistance: effects of age-related changes in the ECM and the biomechanics of the skin

$521,990
Ashani T Weeraratna · Johns Hopkins University · R01 · FY2022 · CA

Precision Medicine For Pediatric Low-Grade Gliomas

$521,946
Daphne A. Haas-Kogan · Dana-Farber Cancer Inst · R01 · FY2016 · NS

Innovative Research for Cancer Nanotechnology (IRCN) for Enhancing Melanoma-specific Immune Responses by the Rational Design of Spherical Nucleic Acids

$521,890
Chad A. Mirkin · Northwestern University · R01 · FY2022 · CA

Intratumoral Cytokine Immunotherapy Studies in Companion Canine Cancer Models

$521,821
Karl D Wittrup · Massachusetts Institute Of Technology · R01 · FY2022 · CA

Differential TGF-Beta Signaling in Bone Microenviroment: Impact on Tumor Growth

$521,804
Theresa A Guise · Indiana University Indianapolis · U01 · FY2014 · CA

Genetic Loss-of-Function Studies of SETD2 in Kidney Tumorigenesis

$521,786
Emily H Cheng · Sloan-Kettering Inst Can Research · R01 · FY2022 · CA

Mechanisms of Murine Turmor Eradication by Immunotherapy

$521,765
Philip D Greenberg · University Of Washington · R01 · FY2014 · CA

Stromal Regulation of Basal Cell Carcinoma Formation

$521,703
Anthony E Oro · Stanford University · R01 · FY2025 · AR

Applying Genomic Dosimeters of UV Damage to Predicting Skin Cancer Risk

$521,690
Douglas E Brash · Yale University · R01 · FY2023 · ES

Mcl-1 in apoptosis and signal transduction: a structure/function approach

$521,604
Maurizio Pellecchia · Sanford Burnham Prebys Medical Discovery Institute · R01 · FY2015 · CA

The distinct role of cysteinyl leukotriene receptor for myeloid-derived suppressive cells

$521,582
Bin Zhang · Northwestern University At Chicago · R01 · FY2022 · CA

(PQ8) Patient- and tumor-specific biomarkers and mechanisms that predict irAEs resulting from checkpoint inhibition

$521,546
Justin M Balko · Vanderbilt University Medical Center · R01 · FY2020 · CA

Project 1- Bioadhesive Sunscreens and Triplet-State Quenchers for Melanoma Prevention

$521,465
Michael Girardi · Yale University · P50 · FY2020 · CA

Immunomodulating Ruthenium Metal Complexes for Melanoma PhotodynamicTherapy

$521,452
Sherri McFarland · University Of Texas Arlington · R01 · FY2021 · CA

The KIT Signaling Pathway as a Therapeutic Target in Melanoma

$521,443
Boris C Bastian · Wistar Institute · P01 · FY2015 · CA

Hemodynamic Noninvasive Skin Cancer Diagnostics

$521,409
Mirianas Chachisvilis · Veriskin, Inc. · R44 · FY2016 · CA

Immunomodulating Ruthenium Metal Complexes for Melanoma Photodynamic Therapy

$521,279
Sherri McFarland · University Of North Carolina Greensboro · R01 · FY2018 · CA

Development of an LXR agonist as first in class therapy for treatment of metastatic melanoma

$521,277
Isabel Kurth · Rgenix, Inc. · R44 · FY2017 · CA

Immunotherapeutic Nanoparticle Delivery to Melanoma With MR-Guided Focused Ultrasound

$521,056
Richard J Price · University Of Virginia · R01 · FY2016 · CA

IL-2 Family Cytokines and their Receptors--Biology of the IL-7/TSLP Systems

$521,044
Warren J Leonard · National Heart, Lung, And Blood Institute · ZIA · FY2021 · HL

Epidemiology of Cancer in a Cohort of Older Women

$520,999
Aaron R Folsom · University Of Minnesota · R01 · FY2007 · CA